查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067506

腫瘤臨床試驗市場規模、佔有率和趨勢分析報告：按階段、研究設計、適應症、地區和細分市場預測（2026-2033 年）

Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase Type, By Study Design, By Indication, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

腫瘤臨床試驗概述

全球腫瘤臨床試驗市場預計到 2025 年將價值 325 億美元，預計到 2033 年將達到 589 億美元，2026 年至 2033 年的複合年成長率為 7.9%。

該市場的成長主要由技術進步、癌症發病率上升以及個人化醫療和細胞/基因療法的進步所驅動，這些因素正在為開發治療方法癌症樣疾病的新方法提供可能。

此外，製藥公司、生物技術公司、非營利組織和合約研究組織 (CRO) 對腫瘤臨床試驗的投入不斷增加，進一步促進了市場成長和先進治療方法的開發。

全球癌症發生率不斷上升，人口老化加劇，生物標記主導的精準腫瘤學迅速發展，以及包括適應性試驗在內的創新檢測方法的應用，預計將推動腫瘤臨床試驗的成長。此外，免疫療法和細胞療法研發管線的拓展、突破性藥物加速核准流程的運用，以及腫瘤領域經驗豐富的合約研究組織（CRO）的參與，都進一步促進了腫瘤臨床試驗市場的發展。這些趨勢源自於申辦者對更快招募病患和提高臨床試驗成功率的需求。精準腫瘤學的興起是另一個關鍵促進因素。次世代定序（NGS）技術能夠識別罕見基因突變，例如KRAS G12C和NTRK融合基因，從而提高治療反應率，儘管其適用族群有限。這一趨勢正在推動多項小規模、多中心研究的開展，這些研究涉及複雜的患者篩檢方案，需要生物資訊整合和中心實驗室的參與。同時，自適應和基於平台的試驗設計正在改變臨床開發過程，它允許在試驗過程中進行設計變更，並減少與低效測試方法相關的時間和成本。

此外，免疫腫瘤學領域的聯合臨床試驗（將查核點抑制劑與創新藥物聯合使用）由於需要監測免疫相關不利事件和延長追蹤期，正變得日益複雜。同時，諸如遠距醫療和電子病患報告結局（ePRO）等分散式試驗要素正被擴大用於長期腫瘤試驗中，尤其是在需要病患轉診至多個研究中心的晚期和轉移性癌症試驗中，這些要素有助於提高受試者的留存率。此外，亞太地區（如印度和中國）臨床試驗數量的增加，是由於這些地區存在大量未接受過治療的患者，以及在這些地區進行試驗具有較高的成本效益。

此外，監管機構持續擴大癌症療法的加速核准項目，採用無惡化生存期（PFS）等替代指標，加快了臨床試驗的階段轉換，並提高了試驗啟動的頻率。然而，癌症療法從I期臨床試驗到核准上市的脫落率高達85%以上，這仍然是一項財務挑戰，限制了中小型生物技術公司的發展。此外，嚴格的病患入組標準以及正在進行的臨床試驗對合格病患的競爭，使得受試者招募困難，並延緩了試驗的完成。此外，可以透過引入人工智慧（AI）來最佳化方案製定，並最大限度地減少篩檢失敗，從而提高臨床實驗試驗中心的效率。另一個機會是擴大真實世界證據和合成對照組的使用，以減少對大規模隨機隊列的依賴。

目錄

第1章 研究方法和範圍

第2章執行摘要

第3章 腫瘤臨床試驗市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 科技情勢
  • 定價模式分析
  • 關稅影響分析
  • 價值鏈分析
  • 市場分析工具

第4章：癌症臨床試驗市場：依試驗階段分類的估計與趨勢分析

  • 癌症臨床試驗市場：基於階段的波動分析
  • 癌症臨床試驗市場估計與預測：按階段分類，2021-2033年
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章：癌症臨床試驗市場：研究設計的估計與趨勢分析

  • 腫瘤臨床試驗市場：依研究設計分類：波動分析
  • 癌症臨床試驗市場估計與預測：依研究設計分類，2021-2033年
  • 干預研究
  • 觀察性研究
  • 擴展准入測試

第6章：腫瘤臨床試驗市場：依適應症分類的估計與趨勢分析

  • 腫瘤臨床試驗市場：依適應症分析波動情形。
  • 腫瘤臨床試驗市場：依適應症分類的估算與預測，2021-2033年
  • 肺癌
  • 乳癌
  • 結腸癌
  • 白血病
  • 攝護腺癌
  • 其他癌症

第7章：腫瘤臨床試驗市場：區域估算與趨勢分析

  • 區域市場概覽
  • 2025年及2033年區域市佔率分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特
    • 阿曼
    • 卡達

第8章 競爭情勢

  • 主要公司分類
    • Market Leaders
    • Emerging Players
  • 2025年市佔率及估值分析（熱圖分析）
  • 公司簡介
    • Astrazeneca
    • Merck & Co., Inc.
    • IQVIA
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Parexel International Corporation
    • Charles River Laboratories
    • Syneos Health
    • Medpace
    • Labcorp Drug Development
    • ICON plc
    • Thermo Fisher Scientific（PPD）
    • WuXi AppTec
Product Code: GVR-4-68039-139-7

Oncology Clinical Trials Market Summary

The global oncology clinical trials market size was estimated at USD 32.5 billion in 2025 and is projected to reach USD 58.9 billion by 2033, growing at a CAGR of 7.9% from 2026 to 2033. The market growth is primarily driven by technological advancements, rising cancer incidence, and improvements in personalized medicine and cell & gene therapies, which are enabling new approaches to developing treatments for cancer-like diseases.

Moreover, increased funding from pharmaceutical and biotech companies, non-profit organizations, and contract research organizations (CROs) for oncology clinical trials is further supporting market growth and the development of advanced modalities.

The rising incidence of cancer worldwide, coupled with an aging population, the rapid growth of biomarker-driven precision oncology, and the adoption of innovative trial methods, including adaptive studies, is likely to impact the growth of oncology clinical trials. Furthermore, the growing drug pipeline of immunotherapy and cell-based treatments, the use of fast-tracked approval pathways for breakthrough drugs, and the use of CROs experienced in oncology collectively fuel the oncology clinical trials market growth. These trends emerge from the need for faster patient recruitment and greater success in clinical trials among sponsors. The emergence of precision oncology is another key driver, as next-generation sequencing (NGS) panels enable the identification of rare genetic mutations such as KRAS G12C and NTRK fusions, thereby limiting patient pools but improving response rates. This trend drives the development of multiple small-scale, multi-site studies with complex patient screening programs that require bioinformatics integration and the involvement of central laboratories. Meanwhile, adaptive and platform trial designs are transforming the clinical development process by enabling mid-trial design changes, saving time and costs associated with inefficient trial methods.

In addition, immuno-oncology combination clinical trials combining checkpoint inhibitors with innovative drugs are complicated by the need to monitor immune-related adverse effects and the longer follow-up period. Furthermore, decentralized study elements such as remote visits and electronic patient-reported outcomes (ePRO) have been used more frequently to retain participants in lengthy oncology trials, especially in advanced-stage metastatic trials, where travel to multiple sites is required. In addition, the growing number of clinical trials in Asia-Pacific countries such as India and China is driven by the large number of treatment-naive patients and the cost-effectiveness of conducting trials.

Moreover, regulatory bodies continue to expand their accelerated approval programs for oncology drugs that use surrogate markers such as progression-free survival, making phase shifts quicker and trial initiation more frequent. However, attrition rates of over 85% from Phase I to approval in oncology drugs pose a financial challenge that limits the approach of smaller biotechnology companies. In addition, strict inclusion criteria for patients and competition among ongoing clinical trials for eligible patients make recruitment difficult and delay study completion. Furthermore, opportunities arise to adopt artificial intelligence (AI) to optimize protocol development and minimize screening failures, thereby improving site efficiency. The other opportunity is to expand the use of real-world evidence and synthetic control arms to minimize reliance on large, randomized cohorts.

Global Oncology Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oncology clinical trials market report based on phase type, study design, indication, and region:

  • Phase Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Interventional Studies
  • Observational Studies
  • Expanded Access Studies
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Prostate Cancer
  • Other Cancers
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
    • Qatar
    • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Phase Type
    • 1.2.2. Study Design
    • 1.2.3. Indication
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Bottom-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Oncology Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence of Cancer
      • 3.2.1.2. Rise in the Number of CROs for Conducting Research Activities
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost Associated with Oncological Clinical Trial
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Oncology Clinical Trials Market: Phase Type Estimates & Trend Analysis

  • 4.1. Oncology Clinical Trials Market, By Phase Type: Segment Dashboard
  • 4.2. Oncology Clinical Trials Market, By Phase Type: Movement Analysis
  • 4.3. Oncology Clinical Trials Market Estimates & Forecasts, By Phase Type, 2021 - 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oncology Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Oncology Clinical Trials Market, By Study Design: Segment Dashboard
  • 5.2. Oncology Clinical Trials Market, By Study Design: Movement Analysis
  • 5.3. Oncology Clinical Trials Market Estimates & Forecasts, By Study Design, 2021 - 2033 (USD Million)
  • 5.4. Interventional Studies
    • 5.4.1. Interventional Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Expanded Access Studies
    • 5.6.1. Expanded Access Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oncology Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Oncology Clinical Trials Market, By Indication: Segment Dashboard
  • 6.2. Oncology Clinical Trials Market, By Indication: Movement Analysis
  • 6.3. Oncology Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
  • 6.4. Lung Cancer
    • 6.4.1. Lung Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Breast Cancer
    • 6.5.1. Breast Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Colorectal Cancer
    • 6.6.1. Colorectal Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Leukemia
    • 6.7.1. Leukemia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Prostate Cancer
    • 6.8.1. Prostate Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Other Cancers
    • 6.9.1. Other Cancers Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oncology Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2025 & 2033
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Australia
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.6. Oman
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.7. Qatar
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Key Participant Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Astrazeneca
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Merck & Co., Inc.
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. IQVIA
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Gilead Sciences, Inc.
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. F. Hoffmann-La Roche Ltd.
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Parexel International Corporation
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Charles River Laboratories
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Syneos Health
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Medpace
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Labcorp Drug Development
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. ICON plc
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Thermo Fisher Scientific (PPD)
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. WuXi AppTec
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 4 Global Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 5 Global Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 6 North America Oncology Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 7 North America Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 8 North America Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 9 North America Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 10 U.S. Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 11 U.S. Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 12 U.S. Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 13 Canada Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 14 Canada Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 15 Canada Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 16 Mexico Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 17 Mexico Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 18 Mexico Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 19 Europe Oncology Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 20 Europe Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 21 Europe Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 22 Europe Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 23 UK Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 24 UK Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 25 UK Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 26 Germany Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 27 Germany Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 28 Germany Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 29 France Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 30 France Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 31 France Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 32 Italy Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 33 Italy Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 34 Italy Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 35 Spain Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 36 Spain Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 37 Spain Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 38 Denmark Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 39 Denmark Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 40 Denmark Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 41 Sweden Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 42 Sweden Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 43 Sweden Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 44 Norway Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 45 Norway Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 46 Norway Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific Oncology Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 51 Japan Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 52 Japan Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 53 Japan Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 54 China Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 55 China Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 56 China Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 57 India Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 58 India Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 59 India Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 60 Australia Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 61 Australia Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 62 Australia Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 63 Thailand Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 64 Thailand Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 65 Thailand Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 66 South Korea Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 67 South Korea Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 68 South Korea Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 69 Latin America Oncology Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 70 Latin America Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 71 Latin America Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 72 Brazil Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 73 Brazil Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 74 Brazil Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 75 Argentina Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 76 Argentina Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 77 Argentina Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 78 Middle East & Africa Oncology Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 79 Middle East & Africa Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 81 South Africa Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 82 South Africa Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 83 South Africa Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 87 UAE Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 88 UAE Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 89 UAE Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 91 Kuwait Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 92 Kuwait Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 93 Oman Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 94 Oman Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 95 Oman Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 96 Qatar Oncology Clinical Trials Market Estimates and Forecasts, by Phase Type, 2021 - 2033 (USD Million)
  • Table 97 Qatar Oncology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 98 Qatar Oncology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Commodity Flow Analysis
  • Fig. 7 Value-Chain-Based Sizing & Forecasting
  • Fig. 8 QFD Model Sizing & Forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market Snapshot
  • Fig. 11 Segment Snapshot 1
  • Fig. 12 Segment Snapshot 2
  • Fig. 13 Competitive Landscape Snapshot
  • Fig. 14 Parent market outlook, 2025 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2025 (USD Billion)
  • Fig. 16 Oncology Clinical Trials Market Dynamics
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 PESTEL Analysis
  • Fig. 19 Oncology Clinical Trials Market: Phase Type outlook and key takeaways
  • Fig. 20 Oncology Clinical Trials Market: Phase Type movement analysis
  • Fig. 21 Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Oncology Clinical Trials Market: Study Design outlook and key takeaways
  • Fig. 26 Oncology Clinical Trials Market: Study Design Type movement analysis
  • Fig. 27 Interventional Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Observational Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Expanded Access Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Oncology Clinical Trials Market: Indication Outlook and Key Takeaways
  • Fig. 31 Oncology Clinical Trials Market: Indication Movement Analysis
  • Fig. 32 Lung Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Breast Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Colorectal Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Leukemia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Prostate Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Other Cancers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Regional Marketplace: Key Takeaways
  • Fig. 39 North America Oncology Clinical Trials Market estimates and forecasts, 2021-2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 U.S. Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Spain Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark outsourcing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden outsourcing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway outsourcing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Thailand Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Australia Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Brazil Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Argentina Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 MEA Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 South Africa Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Fig. Key country dynamics
  • Fig. 85 Saudi Arabia Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 UAE Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Kuwait Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Oman Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Qatar Oncology Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)